1 Epidemiology and antibiotic resistance profile of *Helicobacter pylori*

2 infection in Cameroon: a systematic review with meta-analysis

3

First name	Last name	Email	Affiliations
Corinne Raissa	Ngnameko	corinnengnameko@yahoo.fr	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Jean Jacques	Noubiap	noubiapjj@yahoo.fr	Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
Freddy Brice	Simo Nemg	nemgsi@yahoo.fr	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Mohamadou Abdou	Galdima	mohamagaldima@yahoo.fr	Department of Internal Medicine, Faculty of Medicine and Biomedical Sciences, University of Ngaoundéré, Garoua, Cameroon Department of Internal Medicine, Garoua Regional Hospital, Garoua, Cameroon
Guy Roussel	Takuissu-Nguemto	tgroussel@yahoo.fr	Laboratory of nutrition and nutritional Biochemistry, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Sophie	Ngo-Boumso	sophia_lesly@yahoo.fr	Department of Hepato-Gastroenrology, CHU de Cocody, University of Felix Houphouet-Boigny, Abidjan, Côte d'Ivoire
Frederic Nico	Njyou	njyou@yahoo.com	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon
Paul F.	Moundipa	pmoundipa@hotmail.com	Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science University of Yaoundé 1, Yaoundé, Cameroon
Jean Joel	Bigna*	bignarimjj@yahoo.fr	Department of Epidemiology, Centre Pasteur of Cameroon, Yaoundé, Cameroon

4 ***Correspondence to:** Dr. Jean Joel Bigna. Department of Epidemiology and Public Health,
 5 Centre Pasteur of Cameroon, Yaoundé, Cameroon. Email: bignarimjj@yahoo.fr

6 **Word count:** 2,578.

7 **Abstract**

8 **Objectives**

9 Although global epidemiology of *Helicobacter pylori* (HP) infection is well characterized,
10 country-specific figure is more accurate for context-specific tailored interventions. The aim
11 was to determine the prevalence, factors associated with infection, antibiotic resistance
12 profile, and genotypes of HP in Cameroon.

13 **Design**

14 A systematic review with meta-analysis.

15 **Participants**

16 People living in Cameroon regardless of their clinical profile.

17 **Data sources and synthesis**

18 Observational studies published in PubMed, EMBASE, African Index Medicus, African
19 Journals Online, and Health Sciences and Diseases up to October 12th, 2020. Study selection,
20 data extraction, and methodological quality assessment were done by two independent
21 authors. Random-effect meta-analysis served to pool prevalence data.

22 **Results**

23 Fifteen studies were included. None investigated the genotypes of HP. Among symptomatic
24 patients, the most common used test, urea breath test on gastric biopsy, yielded a prevalence
25 57.8% (95% confidence interval (CI): 34.3-79.5) of HP infection. This prevalence
26 significantly varied between 47.0% (95%CI: 43.0-51.0) for antigen test in stool samples and
27 71.2% (95%CI: 59.1-81.9) for Giemsa on gastric biopsy; $p = 0.0006$. One study in
28 asymptomatic children reported the prevalence of 52.3% (95%CI: 44.9-59.6) using antigen
29 test for stool samples. Among the six studies investigating factors associated with HP
30 infection, one performed a multivariable model and identified being student as protective

factor compared to being employed (Odds ratio: 0.09; 95%CI: 0.02–0.49). For antibiotics used for first line treatment, HP was resistant to amoxicillin (85.6-97.1%), metronidazole (93.2-97.9%), and clarithromycin (13.6-44.7%) as reported in two studies.

Limitation

Data were from six of the ten regions of Cameroon, hindering the generalizability of the findings to the country.

Conclusion

This study depicted a high prevalence of HP infection and a worrying resistance profile to first-line antibiotics. When waiting for well-conducted studies, updated guidelines are needed for clinical practice for first-line antibiotic treatment.

Registration

PROSPERO, CRD42020220084.

Keywords

Helicobacter pylori; Antimicrobial resistance; Cameroon; Epidemiology

46 **Strengths and limitations of this study**

- 47 • Not all the 10 regions of the country were represented in this study, hindering the
48 generalizability of the findings.
- 49 • We were not able to substantially investigate sources of heterogeneity in the prevalence of
50 *Helicobacter pylori* infection due to scarcity of data.
- 51 • Evidence investigating factors associated with *Helicobacter pylori* infection are weak and
52 there was scarcity on data exploring antibiotic resistance profile of *Helicobacter pylori*.
- 53 • This study is the first to provide an estimate of the epidemiology and resistance profile of
54 *Helicobacter pylori* in Cameroon.

55

56 Introduction

57 *Helicobacter pylori* (*H. pylori*) is a Gram negative bacterium belonging in the family of
58 *Helicobacteriaceae*. This bacterium has been isolated from feces, saliva and dental plaques,
59 suggesting that transmission is possible by ingestion of food or water contaminated by the
60 feces through the gastro-oral route or by person-to-person transmission.^{1 2} *H. pylori* infection
61 is global public health concern with 4.4. billion people living with *H. pylori* worldwide.³ The
62 global prevalence of *H. pylori* infection is 44.3%, with the prevalence higher in developing
63 countries (50.8%) and in Africa (70.1%) compared to other regions.³ Although *H. pylori*
64 infection would have a protective effect against esophageal adenocarcinoma and Barrett's
65 esophagus;⁴ *H. pylori* infection increases the risk for gastroesophageal reflux, peptic or
66 duodenal ulcer, and colorectal and gastric cancers.⁵⁻⁹ In addition, *H. pylori* infection is also
67 associated with non-gastrointestinal disorders like diabetes, obesity, acute coronary syndrome,
68 periodontitis, nonalcoholic fatty liver, Sjögren syndrome, systemic sclerosis, pre-eclampsia,
69 and infertility.¹⁰⁻²⁰ Therefore, curbing the burden of these diseases requires targeted
70 interventions to eradicate *H. pylori* infection.^{9 21-23} Antibiotic resistance profile would make
71 difficult the eradication of *H. pylori* infection. Globally, primary and secondary resistance
72 rates to clarithromycin, metronidazole, and levofloxacin were $\geq 15\%$ in all WHO regions,
73 except primary clarithromycin resistance in the Americas (10%) and South-East Asia region
74 (10%) and primary levofloxacin resistance in the European region (11%).²³
75 Although the global and regional epidemiology and antibiotic resistance profile of *H. pylori*
76 infection is characterized, country-specific figure is more accurate for context-specific
77 tailored interventions. To date, there is no systematic review summarizing data on the
78 epidemiology and antibiotic resistance profile of *H. pylori* infection in Cameroon. Therefore,
79 the aim was to determine the prevalence, factors associated with infection, antibiotic
80 resistance profile, and genotypes of *H. pylori* infection in populations living in Cameroon.

81 Such data would help policy makers for national and context-specific interventions, would
82 help for advising local clinical guidelines, and highlight gap between current evidence and
83 new research needed in the country.

84

85 **Methods**

86 **Design**

87 The Joanna Briggs Institute guidelines was used for the methodology of this systematic
88 review and meta-analysis.²⁴ This systematic review and meta-analysis was registered with
89 PROSPERO, number CRD42020220084. This review was reported as per PRISMA
90 guidelines.²⁵

91 **Search strategy**

92 We performed a search of PubMed, Excerpta Medica Database (EMBASE), African Index
93 Medicus, African Journals Online, and the Cameroonian local journal Health Sciences and
94 Diseases to identify relevant studies published on *H. pylori* in Cameroon up to October 12th,
95 2020; regardless of the language of publication. Both text words and medical subject heading
96 terms were used. Search strategy conducted in EMBASE is shown in the Appendix
97 (Supplementary Table 1). A manual search that consists in scanning the reference lists of
98 eligible papers and other relevant review articles was applied.

99 **Eligibility criteria**

100 We considered observational (cross-sectional, case-control, and cohort) studies conducted in
101 general population and populations with specific conditions living in Cameroon. *H. pylori*
102 infection had to be laboratory-diagnosed. Studies had to report the prevalence (or enough data
103 to compute this estimate) or factors associated with *H. pylori* infection, or had to investigate
104 genotypes or the relevant antibiotic (azithromycin, clarithromycin, erythromycin,

metronidazole, tetracycline, minocycline, ampicillin, amoxicillin (+ clavulanic acid), levofloxacin, ciprofloxacin, levofloxacin) resistance profile of *H. pylori*.²³ We have not considered studies in which patients self-reported the infection. Studies conducted in Cameroonian living outside Cameroon were not considered.

Study selection

Two review authors independently screened records based on titles and abstracts for eligibility. Full texts of articles deemed potentially eligible were retrieved. Further, these review authors independently assessed the full text of each study for final inclusion. Disagreements when existing were solved through discussion and consensus.

Data extraction and management

Data were extracted using a preconceived data abstraction form. Two review authors independently extracted data including: name of the first author, publication year, study design, setting, sampling method, samples collection period, timing of data collection and analysis, site of recruitment, underlying conditions, number of patients screened, number of patients infected with *H. pylori*, diagnostic techniques used, laboratory samples, genotype profile, antibiotic resistance profile, mean age, factors associated with *H. pylori* infection, and proportion of male participants. Disagreements between review authors were reconciled through consensus.

Two review authors assessed the risk of bias in included studies using the tool developed by the Joanna Briggs Institute. Disagreements were solved through discussion and consensus. The following items were considered: sampling method (probabilistic sampling vs. non-probabilistic sampling), diagnostic method of *H. pylori* (direct test [stool antigen test, urea breath test of gastric biopsy samples, culture of gastric biopsy samples, stool culture, PCR] vs.

indirect test [antibody detection, saliva, antigen detection]),²⁶ precision (acceptable vs. low), same procedure for diagnostic of *H. pylori* (yes vs. no).

Data synthesis and analysis

Data analyses used the 'meta' packages of the statistical software R (version 3.6.3, The R Foundation for statistical computing, Vienna, Austria).²⁷ Single arcsine transformation with random-effects meta-analysis model was used to pool prevalence data of *H. pylori* infection.²⁸ Egger's test served to assess the presence of publication bias.²⁹ A $p < 0.10$ on Egger test was considered indicative of statistically significant publication bias.

Heterogeneity was evaluated by the χ^2 test on Cochran's Q statistic,³⁰ which was quantified I^2 values.³¹ The I^2 statistic estimates the percentage of total variation across studies due to true between-study differences rather than chance. In general, I^2 values greater than 60-70% indicate the presence of substantial heterogeneity. We performed a narrative synthesis for antibiotic resistance and factors associated with *H. pylori* infection because of the heterogeneity in reporting these outcomes and scarcity of data.

Results

Study selection and characteristics

We initially identified 77 records and finally retained 15 studies (Figure 1).³²⁻⁴⁶ Agreement between investigators for report selection based on title and abstract was $\kappa = 0.88$, and $\kappa = 1$ for final inclusion. Individual characteristics of included studies are in the Supplementary Table 2.

Studies were published between 2013 and 2019 and data were collected between 2006 and 2018. Fourteen studies were cross-sectional, and one was case control. Fourteen studies were

hospital-based, and one was community-based. Data were from six of the ten regions of the country: Centre, Littoral, East, North-West, South-West, and West. Gastric biopsy was done in 10 studies, blood collection in five studies, and stool collection in three studies. Urea breath test were used in eight studies, antibodies were searched in five studies, antigens in three studies, Giemsa in two studies, and PCR in one study. There were fourteen studies reporting prevalence data, four studies that investigated factors associated with *H. pylori* infection, and two that investigated antimicrobial resistance. None of the studies investigated the genotypes of *H. pylori*. One study was conducted among asymptomatic general population of children and the remaining were conducted among symptomatic patients.

Two studies performed probabilistic sampling and the remaining non-probabilistic sampling. Twelve studies prospectively analysed data and the remaining retrospectively. The response rate was acceptable in 12 studies and not reported in three studies. (Supplementary Table 2).

Prevalence of *Helicobacter pylori* in Cameroon

Twelve studies investigated the prevalence of *H. pylori* infection. Among symptomatic people,^{32 33 35 37-45} the most common used test, urea breath test on gastric biopsy, yielded a prevalence 57.8% (95%CI: 34.3-79.5), with substantial heterogeneity (Table 1). The prevalence of *H. pylori* infection significantly varied between 47.0% (95%CI: 43.0-51.0) for antigen test in stool samples and 71.2% (95%CI: 59.1-81.9) for Giemsa on gastric biopsy (Figure 1), with significant difference between diagnostic methods, $p = 0.0006$ (Table 1). The publication bias was marginal (Table 1).

One study reported the prevalence of *H. pylori* in general population.⁴⁶ The study was conducted among 176 asymptomatic children on stool samples. The prevalence was 52.3% (95%CI: 44.9-59.6) using antigen test.

Factors associated with *Helicobacter pylori* infection in Cameroon

Six studies investigated factors associated with *H. pylori* in symptomatic patients and in general population of children and adults (Table 2).^{32-34 39 40 46} Aminde and colleagues in a retrospective cross-analysis of 451 children and adults with dyspepsia, identified being student (odds ratio [OR]: 0.41; 95%CI: 0.18-0.90) and unemployed/retired (OR: 0.31; 95%CI: 0.11-0.87) as protective factor compared to employed, as well as being HIV-infected (OR: 0.49; 95%CI: 0.15-0.68).³³ In the multivariable model, only being student remained associated with *H. pylori* immunoglobulins G seropositivity (Table 2).³³

The remaining studies did not perform multivariable analysis. Ankouane and colleagues in a 9-year retrospective analysis of 115 children and adolescents with peptic ulcer disease did not identify any factor associated with *H. pylori* infection on gastroduodenal biopsies using rapid urease test.³² Ndebi and colleagues in a cross-sectional study of 160 adults consulting in a primary healthcare setting for medical check-up or with hospital admission identified not washing hands after saddles (OR: 10.74; 95%CI: 5.12-22.54), giving of chewed food by the parents to children (OR: 3.38; 95%CI: 1.54-7.40), and borrow water (OR: 0.25; 95%CI: 0.07-0.91).³⁴ Ndip and colleagues in a cross-sectional study of 176 asymptomatic children identified male sex (OR: 2.67; 95%CI: 1.39-5.17), low socioeconomic status (OR: 2.41; 95%CI: 1.26-4.64), 2-4 persons in the house (OR: 3.09; 95%CI: 1.53-6.28 versus > 4 persons), sucking of thumb/fingers (OR: 6.06; 95%CI: 2.02-19.4), bathing in shared water (OR: 4.10; 95%CI: 1.56-11.2), breastfeeding > 6 months (OR: 0.20; 95%CI: 0.08-0.49; versus < 2 months).^{46 47} Ankouane and colleagues in a cross-sectional study of 171 children and adults identified age > 50 years (RR: 0.73; 95%CI: 0.57-0.93) as factor associated with *H. pylori* infection with rapid urease test on gastric biopsies.⁴⁰ Agbor and colleagues in a cross-sectional study of feces from 500 patients consulting for signs and symptoms of chronic gastritis identified age > 50 years (p = 0.021), level of education (prevalence decrease with

level of education, $p < 0.001$), source of income (prevalence higher in agriculture, trading, service compared to housewife/retired, $p < 0.001$), source of drinking water (prevalence higher for bottled > spring or tap water; $p = 0.006$), increasing duration of gastric symptom ($p = 0.003$), toilet system (higher in leads to drainage compared to closed pit; $p = 0.044$), alcohol consumption ($p = 0.027$), smoking status (higher in occasional smokers compared to regular; $p < 0.001$) associated detection of *H. pylori* antigen.³⁹

Antibiotic resistance profile of *Helicobacter pylori* in Cameroon

Two studies reported antibiotic resistance profile of *H. pylori* (Table 3).^{35 36} Ndip and colleagues analysed 132 gastric biopsy specimens for *H. pylori* resistance against four antibiotics (clarithromycin, tetracycline, amoxicillin, and metronidazole). The proportion of resistance varied from 43.9% for tetracycline to 93.2% for metronidazole.³⁵ In a study by Kouitchou Mabeku and colleagues in 140 gastric biopsy specimens,³⁶ the authors did not find any resistance against azithromycin, ciprofloxacin, and levofloxacin. The resistance was less than 20% for three antibiotics (minocycline, tetracycline, and clarithromycin). The resistance was 47.9% for erythromycin. For the remaining antibiotics, the resistance was higher than 95% (amoxicillin, metronidazole, ampicillin (+ clavulanic acid)).

Discussion

This systematic review with meta-analysis of 15 studies depicted a high prevalence of *H. pylori* infection among different people living in Cameroon using different diagnostic methods. There was a high variability among reported factors associated with this infection. *H. pylori* was resistant to most of antibiotics at 50% level or more.

The prevalence of *H. pylori* infection we found in this study is in the range of estimates reported from other countries of Africa (46.8-87.7%) as well as for other regions of the world

(44.3%, 95% CI: 40.9-47.7).^{3 48} At the turn of the 21st century, the prevalence of *H. pylori* has been declining in highly industrialized countries of the Western world, whereas prevalence has plateaued at a high level in developing (like in Cameroon) and newly industrialized countries.³ The high prevalence in the country may be explained by poor access to adequate sanitation, poor access to clean water, and low socioeconomic status known to be associated with *H. pylori* infection. The overall situation is concerning in the country. For instance, few (51%) family had access to enough water, a fifth of the communities used exclusively unimproved water sources and 52% mixes both unimproved and improved water sources, 31% of the community do not treat drinking water, and only few (67%) people have soap at home and even less have handwashing facilities (63%).⁴⁹ Therefore, curbing the burden of *H. pylori* infection required a broad intervention for improving hygiene, sanitation, and water supply profile in the country. Performing systematic and community testing for *H. pylori* could be explored, however, in a resource-limited setting with high burden of other diseases seems to be unrealistic. A focus should be done for patient with high risk of infection; for instance, those with gastroduodenal symptoms.

At individual level, several factors have been investigated with *H. pylori* infection; however, only one study performed a multivariable model identifying being student as a protective factor compared to being employed. Multiple factors have been identified in the univariable model, however it is difficult to exploit these findings and make recommendations. Therefore, high-quality and well-conducted community-based epidemiological studies are needed to identify risk factors associated with *H. pylori* infection in the country. Such studies would help to identify country-specific risk factors of *H. pylori* infection and adopt related and tailored recommendations.

In Cameroon, first line treatment for *H. pylori* include two main strategies: concomitant quadruple therapy (proton pump inhibitor + amoxicillin + metronidazole + clarithromycin for

14 days) and sequential quadruple therapy (proton pump inhibitor + amoxicillin for 5 days, followed by proton pump inhibitor + metronidazole + clarithromycin for 5 days).⁵⁰ As reported in a study conducted among 165 patients, the most used is the first one (63%).⁵⁰ From this study, the treatment success rate of these strategies were 73.9% without significant difference between them.⁵⁰ However, using these antibiotics in this context is questionable looking at the findings of the two studies on antibiotic resistance we found. *H. pylori* was resistant to amoxicillin (85.6-97.1%), metronidazole (93.2-97.9%), and clarithromycin (13.6-44.7%). Only clarithromycin had profile resistance < 50%. Therefore, all treatment initiation against *H. pylori* should be guided by the antibiotic resistance profile. However, in a resource-limited setting where the resistance profile test is only (but not all) accessible in secondary/tertiary healthcare facilities, this strategy is unrealistic. Therefore, two strategies should be adopted, one guided by antibiotic resistance profile and the second one based on probabilistic nonresistance profile. The last one requires a broad analysis of *H. pylori* antibiotic resistance profile considering actual evidence and performing a nationally-representative and community-based study to design tailored recommendations for context-specific probabilistic and efficacious first-line antibiotic treatment.

The findings of this study should be interpreted with caution. Not all the 10 regions of the country were represented in this study hindering the generalizability of the findings of this study to the entire country. We were not able to substantially investigate sources of heterogeneity in the prevalence of *H. pylori* infection due to scarcity of data, although heterogeneity is practically inevitable in a meta-analysis of prevalence studies. In the absence of a nationally representative population-based study taking into account all regions of the country, this study is the first to provide an estimate of the epidemiology and resistance profile of *H. pylori* in Cameroon without a lot of financial, logistical, and material expenses in the context of a resource-limited country.

273 This study depicted a high prevalence of *H. pylori* infection in both symptomatic and
274 asymptomatic populations. This study also highlights a worrying resistance profile to first-line
275 antibiotics. When waiting for well-conducted studies to identify risk factors associated with
276 *H. pylori* infection and to have a more accurate profile of antibiotic resistance profile, updated
277 guidelines are needed for clinical practice for first-line treatment in the country.

Author contributions: Conception and design: JJB, MAG, CRN, FNN, FBNS. Search strategy: JJB. Study selection: JJB, FBNS. Data extraction: JJB, CRN, FBNS. Data analysis: JJB and JJN. Manuscript drafting: JJB, CRN, JJN. Manuscript revision: JJB, MAG, PFM, CRN, SNB, FNN, JJN, FBNS, GRTN. Guarantor of the review: JJB. Approved the final version of the manuscript: All authors.

Acknowledgements: None.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: We have read and understood BMJ policy on declaration of interests and declare that we have no competing interests.

Data sharing statement: All data relevant to the study are included in the article or uploaded as supplementary information.

References

1. Kayali S, Manfredi M, Gaiani F, et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. *Acta bio-medica : Atenei Parmensis* 2018;89(8-s):72-76. doi: 10.23750/abm.v89i8-S.7947 [published Online First: 2018/12/19]
2. Mladenova I, Durazzo M. Transmission of Helicobacter pylori. *Minerva gastroenterologica e dietologica* 2018;64(3):251-54. doi: 10.23736/s1121-421x.18.02480-7 [published Online First: 2018/02/21]
3. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology* 2017;153(2):420-29. doi: 10.1053/j.gastro.2017.04.022 [published Online First: 2017/05/01]
4. Rokkas T, Pistiolas D, Sechopoulos P, et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2007;5(12):1413-7, 17.e1-2. doi: 10.1016/j.cgh.2007.08.010 [published Online First: 2007/11/13]

5. Mungan Z, Pınarbaşı Şimşek B. Gastroesophageal reflux disease and the relationship with *Helicobacter pylori*. *The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology* 2017;28(Suppl 1):S61-s67. doi: 10.5152/tjg.2017.16 [published Online First: 2017/12/05]
6. de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. *The Lancet Global health* 2020;8(2):e180-e90. doi: 10.1016/s2214-109x(19)30488-7 [published Online First: 2019/12/22]
7. Zuo Y, Jing Z, Bie M, et al. Association between *Helicobacter pylori* infection and the risk of colorectal cancer: A systematic review and meta-analysis. *Medicine (Baltimore)* 2020;99(37):e21832. doi: 10.1097/md.00000000000021832 [published Online First: 2020/09/15]
8. Poorolajal J, Moradi L, Mohammadi Y, et al. Risk factors for stomach cancer: a systematic review and meta-analysis. *Epidemiology and health* 2020;42:e2020004. doi: 10.4178/epih.e2020004 [published Online First: 2020/02/07]
9. Ford AC, Gurusamy KS, Delaney B, et al. Eradication therapy for peptic ulcer disease in *Helicobacter pylori*-positive people. *The Cochrane database of systematic reviews* 2016;4(4):Cd003840. doi: 10.1002/14651858.CD003840.pub5 [published Online First: 2016/04/20]
10. Mansori K, Moradi Y, Naderpour S, et al. *Helicobacter pylori* infection as a risk factor for diabetes: a meta-analysis of case-control studies. *BMC gastroenterology* 2020;20(1):77. doi: 10.1186/s12876-020-01223-0 [published Online First: 2020/03/27]
11. Fang Y, Fan C, Xie H. Effect of *Helicobacter pylori* infection on the risk of acute coronary syndrome: A systematic review and meta-analysis. *Medicine (Baltimore)* 2019;98(50):e18348. doi: 10.1097/md.00000000000018348 [published Online First: 2019/12/20]
12. Wei X, Zhao HQ, Ma C, et al. The association between chronic periodontitis and oral *Helicobacter pylori*: A meta-analysis. *PLoS One* 2019;14(12):e0225247. doi: 10.1371/journal.pone.0225247 [published Online First: 2019/12/12]
13. Liu R, Liu Q, He Y, et al. Association between *Helicobacter pylori* infection and nonalcoholic fatty liver: A meta-analysis. *Medicine (Baltimore)* 2019;98(44):e17781. doi: 10.1097/md.00000000000017781 [published Online First: 2019/11/07]
14. Xu X, Li W, Qin L, et al. Relationship between *Helicobacter pylori* infection and obesity in Chinese adults: A systematic review with meta-analysis. *PLoS One* 2019;14(9):e0221076. doi: 10.1371/journal.pone.0221076 [published Online First: 2019/09/12]
15. Ning L, Liu R, Lou X, et al. Association between *Helicobacter pylori* infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. *European journal of gastroenterology & hepatology* 2019;31(7):735-42. doi: 10.1097/meg.0000000000001398 [published Online First: 2019/04/06]

16. Chen Q, Zhou X, Tan W, et al. Association between *Helicobacter pylori* infection and Sjögren syndrome: A meta-analysis. *Medicine (Baltimore)* 2018;97(49):e13528. doi: 10.1097/md.00000000000013528 [published Online First: 2018/12/14]
17. Li X, Peng L, Shen X, et al. The Association between Infertility and *Helicobacter pylori* Infection: a Meta-Analysis of Case-control Studies. *Clinical laboratory* 2018;64(9):1385-93. doi: 10.7754/Clin.Lab.2018.180206 [published Online First: 2018/10/03]
18. Yong WC, Upala S, Sanguankeo A. *Helicobacter pylori* infection in systemic sclerosis: a systematic review and meta-analysis of observational studies. *Clinical and experimental rheumatology* 2018;36 Suppl 113(4):168-74. [published Online First: 2018/05/11]
19. Bellos I, Daskalakis G, Pergialiotis V. *Helicobacter pylori* infection increases the risk of developing preeclampsia: A meta-analysis of observational studies. *International journal of clinical practice* 2018;72(2) doi: 10.1111/ijcp.13064 [published Online First: 2018/02/02]
20. Nourollahpour Shiadeh M, Riahi SM, Adam I, et al. *Helicobacter pylori* infection and risk of preeclampsia: a systematic review and meta-analysis. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2019;32(2):324-31. doi: 10.1080/14767058.2017.1378331 [published Online First: 2017/09/12]
21. Du LJ, Chen BR, Kim JJ, et al. *Helicobacter pylori* eradication therapy for functional dyspepsia: Systematic review and meta-analysis. *World journal of gastroenterology* 2016;22(12):3486-95. doi: 10.3748/wjg.v22.i12.3486 [published Online First: 2016/03/30]
22. Lee YC, Chiang TH, Chou CK, et al. Association Between *Helicobacter pylori* Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology* 2016;150(5):1113-24.e5. doi: 10.1053/j.gastro.2016.01.028 [published Online First: 2016/02/03]
23. Savoldi A, Carrara E, Graham DY, et al. Prevalence of Antibiotic Resistance in *Helicobacter pylori*: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology* 2018;155(5):1372-82.e17. doi: 10.1053/j.gastro.2018.07.007 [published Online First: 2018/07/11]
24. Santos WMD, Secoli SR, Püschel VAA. The Joanna Briggs Institute approach for systematic reviews. *Revista latino-americana de enfermagem* 2018;26:e3074. doi: 10.1590/1518-8345.2885.3074 [published Online First: 2018/11/22]
25. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ (Clinical research ed)* 2009;339:b2700. doi: 10.1136/bmj.b2700 [published Online First: 2009/07/23]

26. Patel SK, Pratap CB, Jain AK, et al. Diagnosis of *Helicobacter pylori*: what should be the gold standard? *World journal of gastroenterology* 2014;20(36):12847-59. doi: 10.3748/wjg.v20.i36.12847 [published Online First: 2014/10/04]
27. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evidence-based mental health* 2019;22(4):153-60. doi: 10.1136/ebmental-2019-300117 [published Online First: 2019/09/30]
28. Schwarzer G, Chemaitelly H, Abu-Raddad LJ, et al. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. *Research synthesis methods* 2019;10(3):476-83. doi: 10.1002/jrsm.1348 [published Online First: 2019/04/05]
29. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed)* 1997;315(7109):629-34. doi: 10.1136/bmj.315.7109.629 [published Online First: 1997/10/06]
30. Cochran WG. The Combination of Estimates from Different Experiments. *Biometrics* 1954;10(1):101-29. doi: 10.2307/3001666
31. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed)* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First: 2003/09/06]
32. Ankouane F, Ngatcha G, Tagni-Sartre T-S, et al. *Helicobacter Pylori* Infection and Peptic Ulcer Disease in Children and Adolescents from the Age Range of 6 to 18 Years Old in Yaounde (Cameroon). *Health Sciences and Diseases* 2015;16:1-6.
33. Aminde JA, Dedino GA, Ngwasiri CA, et al. *Helicobacter pylori* infection among patients presenting with dyspepsia at a primary care setting in Cameroon: seroprevalence, five-year trend and predictors. *BMC Infect Dis* 2019;19(1):30. doi: 10.1186/s12879-019-3677-0 [published Online First: 2019/01/10]
34. Ndebi M, Guimtsop Y, Tamokou JDD. The assessment of risk factors, lipid profile, uric acid and alanine aminotransferase in *Helicobacter pylori*-positive subjects. *International Journal of Research in Medical Sciences* 2018;6:2889-94. doi: 10.18203/2320-6012.ijrms20183623
35. Ndip RN, Malange Takang AE, Ojongokpoko JE, et al. *Helicobacter pylori* isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: current status of antibiogram. *Tropical medicine & international health : TM & IH* 2008;13(6):848-54. doi: 10.1111/j.1365-3156.2008.02062.x [published Online First: 2008/04/04]
36. Kouitcheu Mabeku LB, Eyoun Bille B, Tepap Zemnou C, et al. Broad spectrum resistance in *Helicobacter pylori* isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. *BMC infectious diseases* 2019;19(1):880. doi: 10.1186/s12879-019-4536-8 [published Online First: 2019/10/24]

37. Ankouane F, Ngatcha G, Kowo M, et al. Analyse démographique et endoscopique des patients atteints d'ulcère gastroduodénal à Yaoundé au Cameroun : qu'est ce qui a changé depuis les années 1990 ? *Médecine d'Afrique Noire* 2016
38. Nell S, Eibach D, Montano V, et al. Recent Acquisition of *Helicobacter pylori* by Baka Pygmies. *PLoS Genetics* 2013;9(9) doi: 10.1371/journal.pgen.1003775
39. Agbor NE, Esemu SN, Ndip LM, et al. *Helicobacter pylori* in patients with gastritis in West Cameroon: prevalence and risk factors for infection. *BMC research notes* 2018;11(1):559. doi: 10.1186/s13104-018-3662-5
40. Andoulo FA, Noah DN, Taghi-Sartre M, et al. [Epidemiology of infection *Helicobacter pylori* in Yaoundé: specificity of the African enigma]. *The Pan African medical journal* 2013;16:115.
41. Ankouane F, Noah DN, Enyime FN, et al. *Helicobacter pylori* and precancerous conditions of the stomach: The frequency of infection in a cross-sectional study of 79 consecutive patients with chronic antral gastritis in yaoundé, cameroon. *Pan African Medical Journal* 2015;20 doi: 10.11604/pamj.2015.20.52.5887
42. Ebule AI, Longdoh AN, Paloheimo IL. *Helicobacter pylori* infection and atrophic gastritis. *African Health Sciences* 2013;13(1):112-17.
43. Eloumou Bagnaka SA, Luma Namme H, Noah Noah D, et al. Risk factors associated with gastroduodenal lesions in a Douala referral hospital (Cameroon). *Medecine et sante tropicales* 2016;26(1):104-09. doi: 10.1684/mst.2015.0521
44. Kouitchou Mabeku LB, Bello Epesse M, Fotsing S, et al. Stool Antigen Testing, a Reliable Noninvasive Method of Assessment of *Helicobacter pylori* Infection Among Patients with Gastro-duodenal Disorders in Cameroon. *Digestive Diseases and Sciences* 2020 doi: 10.1007/s10620-020-06219-0
45. Ankouane F, Kowo M, Ndjitoyap Ndam AW, et al. The Prevalence of *Helicobacter Pylori* Infection and Peptic Ulcer Disease in HIV-Positive Patients with Gastrointestinal Symptoms Is not Related to Absolute CD4 Counts: A Case-Control Study. *Health Sci Dis* 2016;17(1):1-5.
46. Ndip RN, Malange AE, Akoachere JFT, et al. *Helicobacter pylori* antigens in the faeces of asymptomatic children in the Buea and Limbe health districts of Cameroon: A pilot study. *Tropical Medicine and International Health* 2004;9(9):1036-40. doi: 10.1111/j.1365-3156.2004.01299.x
47. Ndip RN, Malange AE, Akoachere JFT, et al. *Helicobacter pylori* antigens in the faeces of asymptomatic children in the Buea and Limbe health districts of Cameroon: a pilot study. 2004;9(9):1036-40. doi: <https://doi.org/10.1111/j.1365-3156.2004.01299.x>
48. Zamani M, Ebrahimitabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of *Helicobacter pylori* infection. *Alimentary pharmacology & therapeutics* 2018;47(7):868-76. doi: 10.1111/apt.14561 [published Online First: 2018/02/13]

49. Reach. Water, sanitation, and hygiene needs assessment: Cameroon report: Reach; 2019
[Available from:
https://reliefweb.int/sites/reliefweb.int/files/resources/reach_cmr_report_wash_assessment_december_2018.pdf accessed Jan 09 2020.
50. Ndjitoyp Ndam AW, Kowo MP, Atangana Messi A, et al. Efficacité de la première ligne de traitement pour l'éradication d'*Helicobacter pylori* dans un pays d'Afrique subsaharienne. JFHOD: SOCIÉTÉ SAVANTE DES MALADIES ET CANCERS DE L'APPAREIL DIGESTIF, 2020.

474 **Table 1. Prevalence of *Helicobacter pylori* in patients with gastro-intestinal symptoms or disease* and in children general population**

	Prevalence (95%CI)	N studies	N participants	I ² , %	P heterogeneity	P Egger	P difference
Symptomatic							
• Antigen test	47.0 (43.0-51.0)	2	600	0.0	0.660	NA	0.0006
• PCR, DNA	54.5 (47.2-61.7)	1	178	NA	NA	NA	
• Urea breath test	57.8 (34.3-79.5)	8	1,298	98.5	< 0.0001	0.047	
• Antibody test	62.1 (46.2-76.8)	4	1,190	96.4	< 0.0001	0.074	
• Giemsa	71.2 (59.1-81.9)	1	59	NA	NA	NA	
Asymptomatic children							
• Antigen test	52.3 (44.9-59.6)	1	176	NA	NA	NA	

475 PCR: polymerase chain reaction, DNA: deoxyribonucleic acid, NA: not applicable.

476 * include dyspepsia, gastritis, gastric pain, gastroduodenal ulcer,

477 **Table 2. Factors associated with *Helicobacter pylori* infection in populations living in Cameroon**
478

Author, year	Population	Diagnostic of <i>H. pylori</i>	Study design	Factors searched	Factors identified in univariable analysis	Factors identified in multivariable analysis
Aminde, 2019 ³³	451 Children and adults (7-96 years) with dyspepsia	Detection of <i>H. pylori</i> IgG antibodies in serum	Retrospective cross-sectional analysis or medical dossiers	Sex, age, marital status, educational level, religion, employment status, HIV status	Employed versus student OR: 0.31; 95%CI: 0.11–0.87; $p = 0.025$; or versus unemployed/retired OR: 0.41; 95%CI: 0.18–0.90; $p = 0.027$)	Employed versus student (OR: 0.09 (95%CI: 0.02–0.49; $p = 0.005$))
Ankouane, 2015 ³²	115 Children and adolescents (6-18 years) with peptic ulcer	Rapid urease test of gastro-duodenal biopsies	Retrospective cross-sectional analysis of medical dossiers	Sex, age, localization of ulcer (gastric, duodenal, or both), pain	None identified	Not performed
Ndebi, 2018 ³⁴	160 Adults (31+ years) consulting in primary healthcare setting for medical check-up or admitted in hospital	Detection of <i>H. pylori</i> IgG antibodies in serum	Cross-sectional analysis	Sex, age, marital status, profession, educational level, physical activity, smoking status, alcohol consumption, water source for drinking, washing hands after saddles, eat into same dish, abdominal pain, digestive discomfort, anorexia/thinness, anemia, and giving of chewed food by the parents to children	Not washing hands after saddles (OR: 10.74; 95%CI: 5.12-22.54; $p < 0.001$); giving of chewed food by the parents to children (OR: 3.38; 95%CI: 1.54-7.40; $p = 0.002$); borrow of water (OR: 0.25; 95%CI: 0.07-0.91; $p = 0.025$)	Not performed
Ndip, 2004 ⁴⁷	176 Asymptomatic children	Detection of <i>H. pylori</i> antigens in feces	Cross-sectional analysis	Sex, age, socioeconomic status, number of persons in the house, number of bedrooms in the house, sucking of thumb/fingers, bathing in same water, antibiotic treatment, breastfeeding time	Male sex (OR: 2.67; 95%CI: 1.39-5.17; $p = 0.002$), low socioeconomic status (OR: 2.41; 95%CI: 1.26-4.64; $p = 0.006$), 2-4 persons in the house (OR: 3.09; 95%CI: 1.53-6.28; $p = 0.001$ versus > 4 persons), sucking of thumb/fingers (OR: 6.06; 95%CI: 2.02-19.4; $p = 0.0004$), bathing in same water (OR: 4.10; 95%CI: 1.56-11.2; $p = 0.0023$), breastfeeding > 6	Not performed

					months (OR: 0.20; 95%CI: 0.08-0.49; p = 0.001 versus < 2 months)	
Ankouane, 2013 ⁴⁰	171 children and adults (9-82 years) referred for endoscopy with clinical symptoms and signs gastro-duodenal disease	Rapid urease test of gastro-duodenal biopsies	Cross-sectional analysis	Sex, age, area of habitation, socio-economic status, non-steroid anti-inflammatory drug user	Age > 50 years (RR: 0.73; 95%CI: 0.57-0.93; p = 0.004 versus Age < 40 years)	Not performed
Agbor, 2018 ³⁹	500 consulting for signs and symptoms of chronic gastritis	Detection of <i>H. pylori</i> antigens in feces	Cross-sectional analysis	Sex, age, level of education, source of income, source of drinking water, duration of gastritis symptoms, household population, toileting system, alcohol consumption, smoking status	Age > 50 years (p = 0.021), level of education (prevalence decrease with level of education, p < 0.001), source of income (prevalence higher in agriculture, trading, service compared to housewife/retired, p < 0.001), source of drinking water (prevalence higher for bottled > spring or tapwater; p = 0.006), increasing duration of gastric symptom (p = 0.003), toilet system (higher in leads to drainage compared to closed pit; p = 0.044), alcohol consumption (p = 0.027), higher in occasional smokers compared to regular (p < 0.001)	Not performed

479 *H. pylori*: *Helicobacter pylori*; CI: confidence interval ; OR : odds ratio ; Ig : immunoglobulins; RR: risk ratio

Table 3. Antibiotic resistance profile of *Helicobacter pylori* in Cameroon

Author	Sample	Description of antibiotics resistance
Kouitcheu Mabeku, 2019 ³⁶	140 gastric biopsy specimens	Azithromycin 0/140; 0% Ciprofloxacin 0/140; 0% Levofloxacin 0/140; 0% Minocycline 1/140; 0.7% Tetracycline 4/140; 2.9% Clarithromycin 19/140; 13.6% Erythromycin 67/140; 47.9% Amoxicillin 136/140; 97.1% Metronidazole 137/140; 97.9% Ampicillin 140/140; 100% Amoxicillin + clavulanic acid 140/140; 100%
Ndip, 2008 ³⁵	132 gastric biopsy specimens	Tetracycline 58/132; 43.9% Clarithromycin 59/132; 44.7% Amoxicillin 113/132; 85.6% Metronidazole 123/132; 93.2%

483 **Figures' legend**

484 **Figure 1. Study flow diagram**

485

486 **Figure 2. Prevalence of *Helicobacter pylori* in Cameroon according to different**

487 **diagnostic methods in symptomatic patients**

488 PCR: polymerase chain reaction, DNA: deoxyribonucleic acid